tiprankstipranks
Vera Therapeutics, Inc. (VERA)
NASDAQ:VERA
US Market
VERA
Vera Therapeutics
RESEARCH TOOLSreports
Want to see VERA full AI Analyst Report?

Vera Therapeutics (VERA) Stock Forecast & Price Target

868 Followers
See the Price Targets and Ratings of:

VERA Analyst Ratings

Strong Buy
14Ratings
Strong Buy
13 Buy
1 Hold
0 Sell
Based on 14 analysts giving stock ratings to
Vera
Therapeutics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

VERA Stock 12 Month Forecast

Average Price Target

$78.71
▲(122.04% Upside)
Based on 14 Wall Street analysts offering 12 month price targets for Vera Therapeutics in the last 3 months. The average price target is $78.71 with a high forecast of $100.00 and a low forecast of $34.00. The average price target represents a 122.04% change from the last price of $35.45.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"19":"$19","60":"$60","101":"$101","39.5":"$39.5","80.5":"$80.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":100,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$100.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":78.71428571428571,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$78.71</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":34,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$34.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[19,39.5,60,80.5,101],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,32.1,37.323076923076925,42.54615384615385,47.769230769230774,52.99230769230769,58.21538461538462,63.43846153846154,68.66153846153847,73.88461538461539,79.1076923076923,84.33076923076923,89.55384615384617,94.77692307692308,{"y":100,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,32.1,35.68571428571428,39.27142857142857,42.857142857142854,46.44285714285714,50.028571428571425,53.614285714285714,57.199999999999996,60.78571428571428,64.37142857142857,67.95714285714286,71.54285714285714,75.12857142857142,{"y":78.71428571428571,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,32.1,32.246153846153845,32.392307692307696,32.53846153846154,32.684615384615384,32.830769230769235,32.97692307692308,33.12307692307692,33.26923076923077,33.41538461538462,33.56153846153846,33.707692307692305,33.853846153846156,{"y":34,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":20.95,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.61,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.79,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.46,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":50.64,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":45.28,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":40.42,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":40.5,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":35.2,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.94,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":42.66,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.1,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$100.00Average Price Target$78.71Lowest Price Target$34.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
H.C. Wainwright Analyst forecast on VERA
Arthur He CFA
H.C. Wainwright
H.C. Wainwright
$125→$90
Buy
153.88%
Upside
Reiterated
08/12/26
Analyst Maintains Buy on Vera Therapeutics, Cutting Trutakna Price Target to $90 Amid Rising IgAN Competition
Wells Fargo Analyst forecast on VERA
Mohit Bansal
Wells Fargo
Wells Fargo
$70
Buy
97.46%
Upside
Assigned
08/12/26
Wells Fargo Issues a Buy Rating on Vera Therapeutics (VERA)
Jefferies Analyst forecast on VERA
Unknown Analyst
Jefferies
Not Ranked
Jefferies
$60→$59
Buy
66.43%
Upside
Reiterated
08/11/26
Jefferies Sticks to Its Buy Rating for Vera Therapeutics (VERA)
TD Cowen Analyst forecast on VERA
Ritu Baral
TD Cowen
TD Cowen
$78
Buy
120.03%
Upside
Reiterated
08/11/26
Analyst Sees Vera Well Positioned for Trutakna IgAN Launch, Sustained Uptake and Long‑Term Value Creation
LifeSci Capital Analyst forecast on VERA
Rami Katkhuda
LifeSci Capital
LifeSci Capital
$90
Buy
153.88%
Upside
Reiterated
08/11/26
Analyst Reiterates Buy on Vera as Trutakna Launch and IgAN Pipeline Progress Support Maintained $90 Price Target
Wedbush Analyst forecast on VERA
Laura Chico
Wedbush
Wedbush
$43→$34
Hold
-4.09%
Downside
Reiterated
08/11/26
Vera Therapeutics price target lowered to $34 from $43 at WedbushVera Therapeutics price target lowered to $34 from $43 at Wedbush
Raymond James Analyst forecast on VERA
Ryan Deschner
Raymond James
Raymond James
$84
Buy
136.95%
Upside
Reiterated
08/11/26
Vera Therapeutics price target raised to $84 from $78 at Raymond JamesVera Therapeutics price target raised to $84 from $78 at Raymond James
Cantor Fitzgerald Analyst forecast on VERA
Pete Stavropoulos
Cantor Fitzgerald
Cantor Fitzgerald
$100
Buy
182.09%
Upside
Reiterated
08/10/26
Analysts Offer Insights on Healthcare Companies: Clinigence Holdings (NASDAQ: NUTX), Vera Therapeutics (NASDAQ: VERA) and Solid Biosciences (NASDAQ: SLDB)
Bank of America Securities Analyst forecast on VERA
Dina Ramadane
Bank of America Securities
Bank of America Securities
$70→$66
Buy
86.18%
Upside
Reiterated
08/10/26
Vera Therapeutics (VERA) Gets a Buy from Bank of America Securities
Evercore ISI Analyst forecast on VERA
Gavin Clark-Gartner
Evercore ISI
Evercore ISI
$91
Buy
156.70%
Upside
Reiterated
07/09/26
Analysts Are Bullish on These Healthcare Stocks: Marker Therapeutics (MRKR), Tenax Therapeutics (TENX)
Guggenheim Analyst forecast on VERA
Vamil Divan
Guggenheim
Guggenheim
$56→$76
Buy
114.39%
Upside
Reiterated
07/08/26
FDA Approval and Extended Exclusivity of Trutakna Drive Vamil Divan to Reiterate Buy on Vera and Raise Price Target from $56 to $76
Goldman Sachs Analyst forecast on VERA
Paul Choi
Goldman Sachs
Goldman Sachs
$90
Buy
153.88%
Upside
Reiterated
06/05/26
Analysts Are Bullish on Top Healthcare Stocks: Vera Therapeutics (VERA), OrthoPediatrics (KIDS)
Wolfe Research Analyst forecast on VERA
Andy Chen
Wolfe Research
Wolfe Research
$88
Buy
148.24%
Upside
Reiterated
06/02/26
Analysts Offer Insights on Healthcare Companies: Ardent Health Partners, Inc. (NYSE: ARDT), Vera Therapeutics (NASDAQ: VERA) and Spyre Therapeutics (NASDAQ: SYRE)
J.P. Morgan Analyst forecast on VERA
Anupam Rama
J.P. Morgan
J.P. Morgan
$90→$86
Buy
142.60%
Upside
Reiterated
05/22/26
Analysts' Top Healthcare Picks: Concentra Group Holdings Parent, Inc. (CON), Vera Therapeutics (VERA)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
H.C. Wainwright Analyst forecast on VERA
Arthur He CFA
H.C. Wainwright
H.C. Wainwright
$125→$90
Buy
153.88%
Upside
Reiterated
08/12/26
Analyst Maintains Buy on Vera Therapeutics, Cutting Trutakna Price Target to $90 Amid Rising IgAN Competition
Wells Fargo Analyst forecast on VERA
Mohit Bansal
Wells Fargo
Wells Fargo
$70
Buy
97.46%
Upside
Assigned
08/12/26
Wells Fargo Issues a Buy Rating on Vera Therapeutics (VERA)
Jefferies Analyst forecast on VERA
Unknown Analyst
Jefferies
Not Ranked
Jefferies
$60→$59
Buy
66.43%
Upside
Reiterated
08/11/26
Jefferies Sticks to Its Buy Rating for Vera Therapeutics (VERA)
TD Cowen Analyst forecast on VERA
Ritu Baral
TD Cowen
TD Cowen
$78
Buy
120.03%
Upside
Reiterated
08/11/26
Analyst Sees Vera Well Positioned for Trutakna IgAN Launch, Sustained Uptake and Long‑Term Value Creation
LifeSci Capital Analyst forecast on VERA
Rami Katkhuda
LifeSci Capital
LifeSci Capital
$90
Buy
153.88%
Upside
Reiterated
08/11/26
Analyst Reiterates Buy on Vera as Trutakna Launch and IgAN Pipeline Progress Support Maintained $90 Price Target
Wedbush Analyst forecast on VERA
Laura Chico
Wedbush
Wedbush
$43→$34
Hold
-4.09%
Downside
Reiterated
08/11/26
Vera Therapeutics price target lowered to $34 from $43 at WedbushVera Therapeutics price target lowered to $34 from $43 at Wedbush
Raymond James Analyst forecast on VERA
Ryan Deschner
Raymond James
Raymond James
$84
Buy
136.95%
Upside
Reiterated
08/11/26
Vera Therapeutics price target raised to $84 from $78 at Raymond JamesVera Therapeutics price target raised to $84 from $78 at Raymond James
Cantor Fitzgerald Analyst forecast on VERA
Pete Stavropoulos
Cantor Fitzgerald
Cantor Fitzgerald
$100
Buy
182.09%
Upside
Reiterated
08/10/26
Analysts Offer Insights on Healthcare Companies: Clinigence Holdings (NASDAQ: NUTX), Vera Therapeutics (NASDAQ: VERA) and Solid Biosciences (NASDAQ: SLDB)
Bank of America Securities Analyst forecast on VERA
Dina Ramadane
Bank of America Securities
Bank of America Securities
$70→$66
Buy
86.18%
Upside
Reiterated
08/10/26
Vera Therapeutics (VERA) Gets a Buy from Bank of America Securities
Evercore ISI Analyst forecast on VERA
Gavin Clark-Gartner
Evercore ISI
Evercore ISI
$91
Buy
156.70%
Upside
Reiterated
07/09/26
Analysts Are Bullish on These Healthcare Stocks: Marker Therapeutics (MRKR), Tenax Therapeutics (TENX)
Guggenheim Analyst forecast on VERA
Vamil Divan
Guggenheim
Guggenheim
$56→$76
Buy
114.39%
Upside
Reiterated
07/08/26
FDA Approval and Extended Exclusivity of Trutakna Drive Vamil Divan to Reiterate Buy on Vera and Raise Price Target from $56 to $76
Goldman Sachs Analyst forecast on VERA
Paul Choi
Goldman Sachs
Goldman Sachs
$90
Buy
153.88%
Upside
Reiterated
06/05/26
Analysts Are Bullish on Top Healthcare Stocks: Vera Therapeutics (VERA), OrthoPediatrics (KIDS)
Wolfe Research Analyst forecast on VERA
Andy Chen
Wolfe Research
Wolfe Research
$88
Buy
148.24%
Upside
Reiterated
06/02/26
Analysts Offer Insights on Healthcare Companies: Ardent Health Partners, Inc. (NYSE: ARDT), Vera Therapeutics (NASDAQ: VERA) and Spyre Therapeutics (NASDAQ: SYRE)
J.P. Morgan Analyst forecast on VERA
Anupam Rama
J.P. Morgan
J.P. Morgan
$90→$86
Buy
142.60%
Upside
Reiterated
05/22/26
Analysts' Top Healthcare Picks: Concentra Group Holdings Parent, Inc. (CON), Vera Therapeutics (VERA)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
BTSGBrightSpring Health Services, Inc.
AMLXAmylyx Pharmaceuticals Inc
IMMXImmix Biopharma
TNYATenaya Therapeutics
JBIOJade Biosciences
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Vera Therapeutics

3 Months
Anupam RamaJ.P. Morgan
Success Rate
12/25 ratings generated profit
48%
Average Return
+29.78%
Copying Anupam Rama's trades and holding each position for 3 Months would result in 48.00% of your transactions generating a profit, with an average return of +29.78% per trade.
1 Year
Anupam RamaJ.P. Morgan
Success Rate
12/25 ratings generated profit
48%
Average Return
+63.51%
Copying Anupam Rama's trades and holding each position for 1 Year would result in 48.00% of your transactions generating a profit, with an average return of +63.51% per trade.
2 Years
Anupam RamaJ.P. Morgan
Success Rate
14/25 ratings generated profit
56%
Average Return
+42.44%
Copying Anupam Rama's trades and holding each position for 2 Years would result in 56.00% of your transactions generating a profit, with an average return of +42.44% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

VERA Analyst Recommendation Trends

Rating
Apr 26
May 26
Jun 26
Jul 26
Aug 26
Strong Buy
8
13
15
25
26
Buy
3
1
4
4
4
Hold
0
1
1
3
3
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
11
15
20
32
33
In the current month, VERA has received 30 Buy Ratings, 3 Hold Ratings, and 0 Sell Ratings. VERA average Analyst price target in the past 3 months is 78.71.
Each month's total comprises the sum of three months' worth of ratings.

VERA Financial Forecast

VERA Earnings Forecast

Next quarter’s earnings estimate for VERA is -$1.61 with a range of -$1.83 to -$1.39. The previous quarter’s EPS was -$1.52. VERA beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year VERA has Performed in-line its overall industry.
Next quarter’s earnings estimate for VERA is -$1.61 with a range of -$1.83 to -$1.39. The previous quarter’s EPS was -$1.52. VERA beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year VERA has Performed in-line its overall industry.
No data currently available

VERA Sales Forecast

Next quarter’s sales forecast for VERA is $4.28M with a range of $0.00 to $10.00M. The previous quarter’s sales results were $0.00. VERA beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year VERA has Performed in-line its overall industry.
Next quarter’s sales forecast for VERA is $4.28M with a range of $0.00 to $10.00M. The previous quarter’s sales results were $0.00. VERA beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year VERA has Performed in-line its overall industry.

VERA Stock Forecast FAQ

What is VERA’s average 12-month price target, according to analysts?
Based on analyst ratings, Vera Therapeutics, Inc.’s 12-month average price target is 78.71.
    What is VERA’s upside potential, based on the analysts’ average price target?
    Vera Therapeutics, Inc. has 122.04% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is VERA a Buy, Sell or Hold?
          Vera Therapeutics, Inc. has a consensus rating of Strong Buy which is based on 13 buy ratings, 1 hold ratings and 0 sell ratings.
            What is Vera Therapeutics, Inc.’s price target?
            The average price target for Vera Therapeutics, Inc. is 78.71. This is based on 14 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $100.00 ,the lowest forecast is $34.00. The average price target represents 122.04% Increase from the current price of $35.45.
              What do analysts say about Vera Therapeutics, Inc.?
              Vera Therapeutics, Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 14 Wall Streets Analysts.
                How can I buy shares of VERA?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.